Headache News and Research RSS Feed - Headache News and Research

In medicine a headache or cephalalgia is a symptom of a number of different conditions of the head. Some of the causes are benign while others are medical emergencies.
Further Reading
Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Biogen Idec receives marketing authorization from EC for multiple sclerosis drug

Today Biogen Idec announced that the European Commission (EC) has granted marketing authorization for PLEGRIDY (peginterferon beta-1a) as a treatment for adults with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis (MS). [More]
Paracetamol fails to beat placebo at relieving back pain

Paracetamol fails to beat placebo at relieving back pain

Paracetamol is no more effective than placebo at relieving acute lower back pain, according to new clinical trial results. [More]
Narrow networks backlash being felt across the insurance marketplace and campaign trail

Narrow networks backlash being felt across the insurance marketplace and campaign trail

News outlets report that consumer frustration with health law plans' limited choice of doctors and hospitals is emerging in a number of areas. [More]
Immunosignaturing holds promise for accurate diagnosis of Valley Fever

Immunosignaturing holds promise for accurate diagnosis of Valley Fever

On July 5, 2011, a massive wall of dust, ("haboob," in Arabic), blanketed Phoenix, Arizona, creating an awesome spectacle, (or stubborn nuisance, depending on your perspective). Dust storms are a common occurrence in the arid desert environments of the American Southwest. [More]
Combination superior to monotherapy for COPD

Combination superior to monotherapy for COPD

Combination treatment with umeclidinium plus vilanterol improves lung function in patients with chronic obstructive pulmonary disease to a greater extent than with VI or tiotropium monotherapy, results show. [More]
First Edition: July 22, 2014

First Edition: July 22, 2014

Reporting for Kaiser Health News, Susan Jaffe writes: "Medicare officials have allowed patients at dozens of hospitals participating in pilot projects across the country to be exempted from the controversial requirement that limits nursing home coverage to seniors admitted to a hospital for at least three days. [More]
Chikungunya virus transmission occurs in Florida for the first time

Chikungunya virus transmission occurs in Florida for the first time

The chikungunya virus, which is transmitted to people by mosquitoes (Aedes aegypti and Aedes albopictus), was found for the first time in the Americas on islands in the Caribbean in December 2013. Yesterday, the first case of chikungunya in the continental United States was reported in a man from Florida who had not recently travelled outside the United States. [More]
FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

FDA approves Ruconest for treatment of acute attacks in adolescent patients with HAE

The U.S. Food and Drug Administration yesterday approved Ruconest, the first recombinant C1-Esterase Inhibitor product for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema (HAE). [More]
GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK begins shipment of flu vaccines to U.S. for the upcoming 2014-15 season

GSK announced today it has begun shipping FLUARIX QUADRIVALENT (Influenza Vaccine) doses to U.S. healthcare providers. This is the first shipment of GSK’s U.S. flu vaccine supply for the flu season, following licensing and lot-release approval from the U.S. Food and Drug Administration’s Center for Biologics Evaluation and Research. [More]
Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Paracetamol safety and osteoarthritis: an interview with Professor David Hunter, University of Sydney

Firstly, paracetamol has been the first-line recommended treatment for osteoarthritis pain for very many years and, secondly, it is readily available over the counter and can be bought in relatively large quantities. [More]
First step in developing evidence-based concussion guidelines

First step in developing evidence-based concussion guidelines

A research review identifying the clinical indicators most strongly associated with concussion is an important first step in the process of developing evidence-based guidelines for concussion diagnosis, prognosis, and treatment, according to a new report published by Neurosurgery, official journal of the Congress of Neurological Surgeons. [More]

Prisons cut health care costs, but aging inmate population threatens budgets

Health care for prisoners has long taken a bite out of state budgets, but a new report from the Pew Charitable Trusts says prisons have cut back on those costs. They've outsourced some health services, used tele-medicine, and simply incarcerated fewer people. But the aging of the inmate population threatens to drive those costs right back up (Gorenstein, 7/9). [More]
Trial to evaluate safety of FRED- flow diversion system for treatment of aneurysms

Trial to evaluate safety of FRED- flow diversion system for treatment of aneurysms

After Susan Wakulich was told she had an aneurysm, she figured an invasive brain surgery and lengthy recovery lay ahead of her. [More]
Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron, Sanofi report positive results from dupilumab Phase 2b study in moderate-to-severe AD

Regeneron Pharmaceuticals, Inc. and Sanofi today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. [More]
Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

Pain control in osteoarthritis patients: an interview with Dr. Clarence Young, Chief Medical Officer and John Vavricka, President and CEO, Iroko Pharmaceuticals

Osteoarthritis (OA) is one of the most common causes of disability, and inadequate pain control can lead to joint stiffness that may impair mobility for patients. [More]
FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

FDA approves Protein Sciences' strain change amendment for Flublok influenza vaccine

Protein Sciences Corporation announced today that the FDA has approved the Company's strain change amendment for its seasonal influenza vaccine, Flublok. [More]
Perrigo receives final approval from FDA for congestion relief tablets

Perrigo receives final approval from FDA for congestion relief tablets

Perrigo Company today announced that it was the first to receive final approval from the U.S. Food and Drug Administration for its abbreviated new drug application for ibuprofen and phenylephrine hydrochloride tablets, 200 mg/10 mg (over-the-counter), the store brand equivalent to Advil Congestion Relief Tablets, 200 mg/10 mg. [More]
State highlights: Calif. rejecting 'free money'; N.C. Medicaid changes, problems; Ill. readies employer contraception coverage vote

State highlights: Calif. rejecting 'free money'; N.C. Medicaid changes, problems; Ill. readies employer contraception coverage vote

Consumer advocates and some legislators were surprised and frustrated when California health officials recently refused a $6 million donation to help people re-up their Medi-Cal health coverage. Now two senators have proposed an unusual solution: a bill to force the state to accept the offer from The California Endowment (Gorman, 7/4). [More]
Headbanging to Motörhead thought to have caused bleeding in the brain

Headbanging to Motörhead thought to have caused bleeding in the brain

A recent report in the Lancet describes the case of a man who developed bleeding in the brain after headbanging at a Motörhead concert. [More]
UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, Dermira enter into licensing agreement for development, commercialization of Cimzia

UCB, a global biopharmaceutical leader, and Dermira, Inc., a privately held US-based dermatology company, announced today that they have entered into an exclusive licensing agreement for the development and future commercialization of Cimzia (certolizumab pegol) in dermatology. [More]